By Jaime Llinares Taboada
The U.K.'s National Health Service will offer Amgen Inc.'s new drug for lung cancer patients starting in the next few weeks.
The Sotorasib cutting-edge therapy will be initially given to around 600 patients in England per year. "NHS lung cancer patients will be the first in Europe to be offered a revolutionary new drug which stops tumours growing by targeting the so-called 'death star' mutation," the NHS said.
NHS will begin offering the drug following a rapid access agreement with manufacturer Amgen.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
09-10-21 0554ET